Uploaded March 2025 | Updated September 2026, 1 day ago
In a study sponsored by Usona Institute and published on August 31, 2023, in the Journal of the American Medical Association, psilocybin showed promise as a treatment for major depressive disorder (MDD).
JAMA Associate Editor Dr. Donald C. Goff, speaks with publication author Dr. Charles L. Raison, from the Usona Institute, about the study, as well as Dr. Rachel Yehuda from Mount Sinai School of Medicine, who wrote an accompanying editorial about the potential benefits of psychedelic therapies.
Pacific Neuroscience Institute's director of Treatment & Research In Psychedelics Center, Dr. Keith Heinzerling and PNI director Dr. Daniel Kelly were a co-investigators in this study.
In a study sponsored by Usona Institute and published on August 31, 2023, in the Journal of the American Medical Association, psilocybin showed promise as a treatment for major depressive disorder (MDD).
JAMA Associate Editor Dr. Donald C. Goff, speaks with publication author Dr. Charles L. Raison, from the Usona Institute, about the study, as well as Dr. Rachel Yehuda from Mount Sinai School of Medicine, who wrote an accompanying editorial about the potential benefits of psychedelic therapies.
Pacific Neuroscience Institute's director of Treatment & Research In Psychedelics Center, Dr. Keith Heinzerling and PNI director Dr. Daniel Kelly were a co-investigators in this study.
